Wegovy-Maker Novo Faces Calls to Map Out Strategy Beyond Weight-Loss Drugs

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

By Patrick Wingrove LONDON, Sept 21 - Wegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-...

Novo Nordisk Stock at $43.24 Faces a Semaglutide Strategy Test

London, September 20, 2026, 14:10 (BST) Novo’s Capital Markets Day starts Monday at 09:00 BST.NVO closed Friday at $43.24, up 0.12% on 10.36 million shares.Morgan Stanley estimates semaglutide will supply 75% of 2026 sales. Novo Nordisk A/S (NYSE:NVO; CPH:NOVO-B) will open its Capital Markets Day in London on Monday. Its U.S. shares closed Friday at…